ISDA

Deposition Date 2005-10-04

Release Date 2006-02-14

Last Version Date 2024-10-16

Entry Detail

PDB ID:

2B7D

Keywords:

BLOOD CLOTTING

Title:

Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.24 Å

R-Value Free:

0.28

R-Value Work:

0.24

R-Value Observed:

0.25

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor VII
Gene (Uniprot):F7
Chain IDs:B (auth: H)
Chain Length:254
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF00594, PF00008, PF14670 EC:3.4.21.21

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor VII
Gene (Uniprot):F7
Chain IDs:A (auth: L)
Chain Length:152
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF00594, PF00008, PF14670 EC:3.4.21.21

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tissue factor
Gene (Uniprot):F3
Chain IDs:C (auth: T)
Chain Length:218
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P13726 Pfam ID:PF01108, PF09294

Ligand Molecules

C1B

Primary Citation

Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

Young, W.B, Mordenti, J, Torkelson, S, Shrader, W.D, Kolesnikov, A, Rai, R, Liu, L, Hu, H, Leahy, E.M, Green, M.J, Sprengeler, P.A, Katz, B.A, Yu, C, Janc, J.W, Elrod, K.C, Marzec, U.M, Hanson, S.R.Show

Bioorg.Med.Chem.Lett. 16 2037 2041 (2006)

PMID: 16412633 DOI: 10.1016/j.bmcl.2005.12.059

Abstact

Highly selective and potent factor VIIa-tissue factor (fVIIa.TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, and a pharmacodynamic concentration-response model was developed to describe the platelet deposition data. Results for heparin and enoxaparin (Lovenox) in the baboon model are also presented.

Legend

Protein

Chemical

Disease

Primary Citation of related structures